Asia Pacific Immunohematology Market size crossed USD 680 million in 2021 and is projected to showcase around 5% growth rate between 2022 and 2028.
Get more details on this report - Request Free Sample PDF
The rising number diabetes cases and a growing elderly population, who are more sensitive to cardiovascular ailments, will impact the market trends. It is projected that by 2060, more than 1.2 billion Asians will be 65 or older in age. This will lead to age-related chronic diseases and weak immunity among this population.
As China and India are claimed to be among the nations with the most diabetic people, the countries are expected to highly contribute to the industry. By 2025, there will likely be 70 million people in India who have diabetes, and there will likely be 80 million by the end of 2030. Additionally, diabetes is now one of the region’s main contributors towards both cardiovascular disease and blindness.
Asia Pacific Market, By Product
The reagents segment is expected to reach USD 620 million by 2028, due to rise in number of blood-related diseases in the region. There is increased use of reagents in healthcare facilities, including hospitals and clinics, for more frequent blood testing.
Asia Pacific Immunohematology Market, By End-users
The hospitals segment is expected to show tremendous growth during the forecast timeline, owing to the increased utilization of immunohematology products such as analyzers and reagents for blood testing. Hospitals can offer better services and many medical professionals to provide patient care. Also, the growing prevalence of blood disorders coupled with the rising diabetes population in emerging economies will further influence the consumer preference for treatment at hospitals.
Asia Pacific Market, By technology
The gel cards technology segment will witness 30% CAGR through 2028. As gel cards provide multiple advantages over conventional saline tubes, they have become a common choice. Factors contributing to product uptake are that they need less time to use, are more sensitive, completely recordable, and are more stable for extended periods of time. Finding relevant antibodies is easier and more efficient using gel card technology.
Competitive Industry Landscape
Major players involved in the Asia Pacific immunohematology market include Abbott, Becton Dickinson, F. Hoffmann-La Roche Ltd., Hologic, and Bio-Rad Laboratories. Most of these organizations invest heavily toward portfolio expansion as well as to boost their production capacity.